Intravenous Infusions

Most recent documents

Year	Type	Description
2023	Annual Report	Unaudited Financial Statements for the Full Year (12 Months) Ended December 2023
2022	Annual Report	Audited Financial Statements for the Full Year (12 Months) Ended December 2022
2021	Annual Report	Audited Financial Statements for the Full Year (12 Months) Ended December 2021
2023	Interim Statement	Unaudited Financials for the Half Year (6 Months) Ended June 2023
2022	Interim Statement	Unaudited Financials for the Half Year (6 Months) Ended June 2022
2021	Interim Statement	Unaudited Financials for the Half Year (6 Months) Ended June 2021
2024	Corporate Action	EXTENSION OF TIME FOR THE SUBMISSION OF FINANCIAL STATEMENTS
2024	Corporate Action	INTRAVENOUS INFUSIONS PLC UNAUDITED FINANCIAL STATEMENTS FOR THE FULL YEAR (12 MONTHS) ENDED DECEMBER 2023
2023	Corporate Action	INTRAVENOUS INFUSIONS PLC NOTICE OF ANNUAL GENERAL MEETING
2023	Corporate Action	INTRAVENOUS INFUSIONS PLC AUDITED FINANCIAL STATEMENTS FOR THE FULL YEAR (12 MONTHS) ENDED DECEMBER 2022
2023	Corporate Action	XTENSION OF TIME FOR THE SUBMISSION OF FINANCIAL STATEMENTS
2022	Corporate Action	INTRAVENOUS INFUSION PLC NOTICE OF ANNUAL GENERAL MEETING
2022	Corporate Action	INTRAVENOUS INFUSION AUDITED FINANCIAL STATEMENTS FOR THE FULL YEAR (12 MONTHS) ENDED DECEMBER 2021
2022	Corporate Action	NOTICE OF EXTENSION OF TIME FOR THE SUBMISSION OF AUDITED FINANCIAL STATEMENTS FOR YEAR ENDED DECEMBER 2021
2021	Corporate Action	Intravenous Infusions (Facts behind the Figures, September 2021)
2021	Corporate Action	DIVIDEND PAYMENT (2020)
2021	Corporate Action	NTRAVENOUS ANNUAL REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED DECEMBER 2020

Archived documents

Year	Type	Description
2020	Annual Report	Audited Financial Statements for the Full Year (12 Months) Ended December 2020
2019	Annual Report	2019 Annual Report and Financial Statements (Complete)
2018	Annual Report	2018 Annual Report and Financial Statements (Complete)
2017	Annual Report	2017 Annual Report and Financial Statements (Complete)
2016	Annual Report	2016 Annual Report and Financial Statements (Complete)
2015	Annual Report	2015 Annual Report and Financial Statements (Complete)
2020	Interim Statement	Unaudited Financials for the Half Year (6 Months) Ended June 2020
2019	Interim Statement	Unaudited Financials for the Half Year (6 Months) Ended June 2019
2018	Interim Statement	Unaudited Financials for the Half Year (6 Months) Ended June 2018
2017	Interim Statement	Unaudited Financials for the Half Year (6 Months) Ended June 2017
2016	Interim Statement	Unaudited Financials for the Nine Months (Including Third Quarter) Ended September 2016
2016	Interim Statement	Unaudited Financials for the Half Year (Six Months) Ended June 2016
2015	Prospectus	IPO Prospectus
2020	Corporate Action	Appointment of Managing Director and General Manager Technical and Operations
2020	Corporate Action	Notification Appointment of Intellisys Chartered Accountants as Auditors
2020	Corporate Action	Notification of Approved Dividend for 2019 and Appointment of Intellisys (Chartered Accountants) as External Auditor
2020	Corporate Action	Notice of Virtual Annual General Meeting
2020	Corporate Action	Final Dividend, Closure of Register
2020	Corporate Action	Notice of Virtual Annual General Meeting
2020	Corporate Action	Notification of Resignation of Managing Director
2020	Corporate Action	Audited Report and Financial Statements for the Full Year Ended December 2019 (Full)
2019	Corporate Action	Notice of Annual General Meeting - Intravenous Infusions
2019	Corporate Action	Final Dividend and Book Closure
2019	Corporate Action	Audited Financial Statements for Full Year (12 Months) Ended December 2018
2019	Corporate Action	Results of Private Placement Offer
2018	Corporate Action	Appointment of a Director
2018	Corporate Action	Notice of Annual General Meeting - Intravenous Infusions
2018	Corporate Action	Audited Financial Statements for Full Year (12 Months) Ended December 2017
2018	Corporate Action	Notification of Change in Registered Office Address
2017	Corporate Action	Notice of Annual General Meeting - Intravenous Infusions
2017	Corporate Action	GSE Facts Behind the Figures Presentation
2017	Corporate Action	Audited Financial Statements for Full Year (12 Months) Ended December 2016
2017	Corporate Action	Change in Managing Director
2017	Corporate Action	New Managing Director and General Manager
2016	Corporate Action	Notice of Annual General Meeting - Intravenous Infusions
2016	Corporate Action	Audited Financial Statements for Full Year (12 Months) Ended December 2015
2016	Corporate Action	Audited Financial Statements for Full Year (12 Months) Ended December 2015
2015	Corporate Action	IPO Results
2015	Corporate Action	IPO Temporarily Put on Hold